Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort

Yun Liu, Honglian Wang, Xin Wang, Jiaqi Liu, Junjian Li, Xiang Wang, Yun Zhang, Zhigang Bai, Qinghua Zhou, Ying Wu, Yifeng Shen, Xiaoling Weng, Fatao Liu, Jiancheng Guo, Lijun Di, Olivier Gires, Zhongtao Zhang, Yiding Chen, Hongxia WangJournal of Hematology & Oncology 2021 · DOI · OpenAlex

Abstract

Accurate interpretation of BRCA1 and BRCA2 variants is essential for risk assessment and precision treatment in breast cancer. However, existing clinical databases are predominantly based on Caucasian populations, leading to a high rate of Variants of Uncertain Significance (VUS) in other ethnicities. This study analyzed a multicenter cohort of 21,216 Chinese breast cancer patients and 6,434 healthy controls. The findings reveal a 5.5% prevalence of pathogenic variants in patients and identify 13 high-frequency variants unique to the Chinese population. By integrating cohort data with functional assays, the researchers significantly reduced the VUS ratio, providing a critical foundation for ethnicity-specific genetic counseling.

Introduction: The Ethnicity Gap in Genetic Testing

Genetic testing for breast cancer (BC) risk primarily focuses on identifying mutations in the BRCA1 and BRCA2 genes. Pathogenic variants in these genes significantly increase the lifetime risk of breast and ovarian cancers and inform the use of targeted therapies like PARP inhibitors. Despite their clinical importance, the interpretation of these variants relies heavily on databases like ClinVar, which are built largely on data from Caucasian populations.

For patients of non-European descent, this creates a "translation" problem. A genetic variant identified in a Chinese patient might be labeled as a Variant of Uncertain Significance (VUS) simply because it lacks sufficient representation in Western cohorts to be classified as "pathogenic" or "benign." This ambiguity complicates clinical decision-making regarding prophylactic surgeries and treatment strategies. To address this, a large-scale study was conducted to establish an ethnicity-specific landscape of BRCA1/2 variants for the Chinese Han population.

Methodology

The study employed a comprehensive, multi-pronged approach to characterize the genetic landscape:

  1. Large-Scale Cohort Sequencing: Panel-based sequencing was performed on a massive multicenter cohort consisting of 21,216 unselected Chinese Han breast cancer patients and 6,434 healthy controls across 19 medical centers in 11 provinces.
  2. Clinical Phenotyping: Genetic data were correlated with clinical features, including age of onset, histological grade, family history, and molecular subtypes (e.g., Triple-Negative Breast Cancer).
  3. Allele Frequency Analysis: Variants found in healthy controls at frequencies comparable to patients were re-evaluated as likely benign, helping to filter out non-pathogenic VUS.
  4. Functional Validation via SGE: The researchers utilized Saturation Genome Editing (SGE) data—a high-throughput method that assesses the functional impact of every possible single-nucleotide variant in key gene regions. They specifically re-analyzed 100 variants within 13 critical exons of BRCA1.

Key Results and Insights

Ethnicity-Specific "Genetic Dialects"

The study identified 13 pathogenic variants that occurred at high frequencies (>0.45‰) in the Chinese cohort. Remarkably, none of these variants have been reported as high-frequency in Caucasian populations. This discovery underscores the fact that genetic risk is highly dependent on ethnicity and that Western-centric databases may miss or misclassify critical risk factors for Asian patients.

Distribution of BRCA1 (a) and BRCA2 (b) variants across different populations, highlighting variants unique to the Chinese study cohort.

Prevalence and Clinical Correlation

Pathogenic BRCA1/2 variants were found in 5.5% of BC patients compared to 1.1% of healthy controls. These variants were strongly associated with aggressive clinical features, including younger age of onset, higher histological grades, and a family history of cancer. Furthermore, the study noted gene-specific associations: BRCA1 mutations were predominantly linked to Triple-Negative Breast Cancer (TNBC), while BRCA2 mutations were more common in the Luminal B subtype.

Reducing the VUS "Black Box"

Initially, nearly 10% of patients carried a VUS. By leveraging the large-scale cohort data and comparing patient frequencies to healthy controls, the authors successfully reclassified 7 VUS as benign. The integration of SGE data provided even more clarity: of 59 VUS re-analyzed through functional assays, 43.6% (24/55) were reclassified as pathogenic. This reclassification effort reduced the overall VUS ratio in patients from 9.8% to 7.9%.

Discussion and Clinical Implications

The findings demonstrate that functional assays like SGE are powerful "tie-breakers" in variant interpretation. Patients with variants reclassified as "pathogenic" by SGE exhibited clinical phenotypes similar to those with known pathogenic mutations, validating the clinical relevance of high-throughput functional testing.

The study highlights the urgent need for ethnicity-specific classification systems. By integrating allele frequency, clinical history, and functional assay data, clinicians can provide more precise genetic counseling and personalized treatment plans for the Chinese population.

Limitations and Future Directions

While groundbreaking, the study focused exclusively on BRCA1 and BRCA2. Future research should expand to other susceptibility genes such as PALB2, TP53, and ATM. Additionally, while SGE provided invaluable data for specific BRCA1 exons, similar high-throughput functional data for the entire BRCA1 gene and the larger BRCA2 gene are still required to fully resolve the VUS challenge.

Summary updated

Abstract

Accurate interpretation of BRCA1/2 variants is critical for risk assessment and precise treatment of breast cancer (BC). Hence, the establishment of an ethnicity-based BRCA1/2 variant database of the Chinese population is of paramount importance. In this study, panel-based sequencing served to detect BRCA1/2 variants in a Chinese multicenter cohort of 21,216 BC patients and 6434 healthy controls. Overall, the percentage of subjects carrying pathogenic variants was 5.5% (1174/21,216) in BC patients and 1.1% (71/6434) in healthy controls. We identified 13 pathogenic variants as high-frequency variants that had a frequency of > 0.45‰ in BC patients (≥ 10 in 21,216 patients), none of which has been reported in Caucasians. Pathogenic BRCA1/2 variants correlated with younger onset age, higher frequencies of bilateral and triple-negative BC (TNBC), invasive carcinomas, high histological grades, and family history of BC and other cancers. Furthermore, the percentage of the subjects carrying VUS was 9.8% (2071/21,216) in BC patients and 6.9% (446/6434) in healthy controls. Based on our cohort study, we unambiguously reclassified 7 out of the 858 VUS resulting in lower VUS ratio in patients (from 9.8 to 7.9%) as well as in healthy control (from 6.9 to 5.3%). We also re-analyzed the 100 variants in 13 exons (2-5 and 15-23) of the BRCA1 genes using a functional assay (saturation genome editing; SGE). 55 of the 59 VUS had distinct status in the SGE study: 24 (43.6%) were pathogenic, and 31 (56.4%) were benign. Strong ethnicity-specific occurrences of pathogenic BRCA1/2 variants were identified in the Chinese population. Hence, the findings provide rationale and sequencing information for the implementation of BRCA1/2 variants tailored to the Chinese population into clinical risk assessment.
BibTeX
@article{liu2021prevalence,
  author = {Yun Liu and Honglian Wang and Xin Wang and Jiaqi Liu and Junjian Li and Xiang Wang and Yun Zhang and Zhigang Bai and Qinghua Zhou and Ying Wu and Yifeng Shen and Xiaoling Weng and Fatao Liu and Jiancheng Guo and Lijun Di and Olivier Gires and Zhongtao Zhang and Yiding Chen and Hongxia Wang},
  title = {{Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort}},
  journal = {Journal of Hematology \& Oncology},
  year = {2021},
  doi = {10.1186/s13045-020-01010-0},
}
Figure